Highlights

• Progenitor exhausted T cells respond to both anti-PD-1 and combination therapies

• A circulating CD8+ Tem (cTem) subset specifically responds to combination therapy

• HBV-specific CD8+ T cells are enriched in cTem cells

• KIR+ CD8+ and FOXP3+ CD4+ T cells are enriched in non-responsive tumors

Title

Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer

Authors

Xinyi Guo, Hu Nie, Wenwen Zhang, Jiesheng Li, Jing Ge, Bowen Xie, Wenbo Hu, Yicheng Zhu, Na Zhong, Xinmei Zhang, Xiaohong Zhao, Xiaoshuang Wang, Qinli Sun, Kun Wei, Xiaoyuan Chen, Ling Ni, Ting Zhang, Shichun Lu, Lei Zhang, Chen Dong

Journal Information

Cancer Cell (2025)

View at publisher↗